EUVIMEDEUVIMED entdecken
Open Access

Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2

Siriruk Changrob iD, Atsuhiro Yasuhara iD, Suncheol Park iD, Sandhya Bangaru iD, Lei Li iD, Chloe A Troxell iD, Peter J Halfmann iD, Steven A Erickson iD, Nicholas J Catanzaro iD, Meng Yuan iD, Panpan Zhou iD, Min Huang iD und 18 weitere

Journal of Experimental Medicine · 01.12.2025 · 222 (12)

DOI: 10.1084/jem.20251146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 09.10.2025. Verfasst von Siriruk Changrob und 29 weiteren Autor:innen. Beteiligte Einrichtung: Drukier Institute for Children's Health, Weill Cornell Medicine , New York, NY, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Spike Glycoprotein, Coronavirus, Antibodies, Viral, COVID-19. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, Japan Agency for Medical Research and Development, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The S2 subunit of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike is highly conserved across coronavirus strains and therefore is a potential pan-coronavirus vaccine target. However, antibodies targeting this region are typically non-neutralizing. We report herein that S2-targeting antibodies from patients who recovered from SARS-CoV-2 infection bound only closely related sarbecovirus subgenus strains and, like most known S2 antibodies, none of these were neutralizing. In contrast, first-exposure, severe acutely infected COVID-19 patients predominantly induced back-boosted antibody-secreting cells imprinted against past common cold coronavirus strain OC43 that were cross-reactive to as many as five subgenera of betacoronavirus strains and gave rise to antibodies that were neutralizing and protective. The antibodies targeted two different sites: one defined by competition with stem helix antibodies, and the second to an underdescribed epitope at the apex of S2. These findings suggest that S2-targeted vaccines could strategically exploit controlled OC43 priming followed by SARS-CoV-2 boosting to enhance the breadth and quality of protective antibody responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, ViralCOVID-19Antibodies, NeutralizingCommon ColdBroadly Neutralizing AntibodiesHumansCross ReactionsEpitopesAnimalsFemale

Substanzen

Spike Glycoprotein, CoronavirusAntibodies, ViralAntibodies, Neutralizingspike protein, SARS-CoV-2EpitopesBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Drukier Institute for Children's Health, Weill Cornell Medicine , New York, NY, USA.
  • Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
  • Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison , Madison, WI, USA.
  • University of Chicago Department of Medicine, Section of Rheumatology , Chicago, IL, USA.
  • Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Immunology and Microbiology, IAVI Neutralizing Antibody Center and Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.

ORCID-Profile: Siriruk Changrob, Atsuhiro Yasuhara, Suncheol Park, Sandhya Bangaru, Lei Li, Chloe A Troxell, Peter J Halfmann, Steven A Erickson, Nicholas J Catanzaro, Meng Yuan, Panpan Zhou, Min Huang, G Dewey Wilbanks, Joshua J C McGrath, Gagandeep Singh, Sean A Nelson, Yanbin Fu, Nai-Ying Zheng, Sofia M Carayannopoulos, Haley L Dugan, Dustin G Shaw, Christopher T Stamper, Maria Lucia L Madariaga, Florian Krammer, Raiees Andrabi, Dennis R Burton, Andrew B Ward, Ian A Wilson, Yoshihiro Kawaoka, Patrick C Wilson

Förderung

  • National Institute of Allergy and Infectious Diseases
  • Japan Agency for Medical Research and Development
  • NIAID NIH HHS
  • ODCDC CDC HHS
  • Gates Foundation
  • NIH HHS
  • Bill and Melinda Gates Foundation

Zitieren

APA

Changrob, S., Yasuhara, A., Park, S., Bangaru, S., Li, L., Troxell, C. A., Halfmann, P. J., Erickson, S. A., Catanzaro, N. J., Yuan, M., Zhou, P., Huang, M., Wilbanks, G. D., McGrath, J. J. C., Singh, G., Nelson, S. A., Fu, Y., Zheng, N. Y., Carayannopoulos, S. M., …, & Wilson, P. C. (2025). Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2. Journal of Experimental Medicine, 222(12). https://doi.org/10.1084/jem.20251146

Vancouver

Changrob S, Yasuhara A, Park S, Bangaru S, Li L, Troxell CA, et al. Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2. Journal of Experimental Medicine. 2025;222(12). doi:10.1084/jem.20251146

BibTeX
@article{Changrob2025,
  author = {Changrob, Siriruk and Yasuhara, Atsuhiro and Park, Suncheol and Bangaru, Sandhya and Li, Lei and Troxell, Chloe A and Halfmann, Peter J and Erickson, Steven A and Catanzaro, Nicholas J and Yuan, Meng and Zhou, Panpan and Huang, Min and Wilbanks, G Dewey and McGrath, Joshua J C and Singh, Gagandeep and Nelson, Sean A and Fu, Yanbin and Zheng, Nai-Ying and Carayannopoulos, Sofia M and Dugan, Haley L and Shaw, Dustin G and Stamper, Christopher T and Madariaga, Maria Lucia L and Krammer, Florian and Andrabi, Raiees and Burton, Dennis R and Ward, Andrew B and Wilson, Ian A and Kawaoka, Yoshihiro and Wilson, Patrick C},
  title = {Common cold embecovirus imprinting primes broadly neutralizing antibody responses to SARS-CoV-2 S2},
  journal = {Journal of Experimental Medicine},
  year = {2025},
  volume = {222},
  number = {12},
  doi = {10.1084/jem.20251146}
}
Kostenlos starten →